Fig 1.
Disposition of the study patients.
Table 1.
Baseline characteristics of the patients (n = 579).
Fig 2.
Distribution of the patients by the age group.
Fig 3.
Distribution of the patients by the length of follow-up period based on a cut-off value of 1 year.
Fig 4.
Distribution of the patients by the surface topography of breast implants.
Table 2.
Baseline characteristics of the patients by the age group (n = 579).
Table 3.
Baseline characteristics of the patients by the length of follow-up period based on a cut-off value of 1 year (n = 579).
Fig 5.
Distribution of the patients by the trade name of breast implants.
Table 4.
Baseline characteristics of the patients by the trade name of breast implants (n = 579).
Fig 6.
Incidences of postoperative complications.
Table 5.
Incidences of postoperative complications by the age group (n = 579).
Table 6.
Incidences of postoperative complications by the length of follow-up period based on a cut-off value of 1 year (n = 579).
Table 7.
Incidences of postoperative complications by the trade name of breast implants (n = 579).
Fig 7.
Cumulative complication-free survival by the trade name of breast implants.
Fig 8.
Cumulative complication-free hazards by the trade name of breast implants.
Table 8.
Cumulative complication-free survival period by the trade name of breast implants (n = 579).
Table 9.
Cumulative hazards by the trade name of breast implants (n = 579).
Fig 9.
Cumulative complication-free survival by the trade name of breast implants on subgroup analysis.
Fig 10.
Cumulative complication-free hazards by the trade name of breast implants on subgroup analysis.
Table 10.
Incidences of postoperative complications by the trade name of breast implants on subgroup analysis (n = 503).
Table 11.
Cumulative complication-free survival period by the trade name of breast implants on subgroup analysis (n = 503).
Table 12.
Cumulative hazards by the trade name of breast implants on subgroup analysis (n = 503).
Fig 11.
Unapproved materials used for manufacturing of the BellaGel® implants.
Fig 12.
Previous involvement of the manufacturer of the BellaGel® implants in the Poly Implant Prothèse (PIP) fraud.